Please assess the completion status of the following clinical trial:

Trial Title: Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Incompetence of SFJ~* Patients who are candidates for ETA \[laser or radiofrequency ablation (RFA)\]~* Symptomatic varicose veins~* Visible varicose veins~* Ability to comprehend and sign an informed consent and complete study questionnaires in English~Exclusion Criteria:~* Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP Classification of Venous Disorders)~* Patients who have active ulceration on the leg to be treated (Clinical Finding C6, as assessed by CEAP Classification of Venous Disorders)~* Leg obesity impairing the ability to access the vein to be treated and/or to apply post-procedure compression bandaging and stockings~* Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion~* Deep venous reflux unless clinically insignificant in comparison to superficial reflux~* Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings~* Reduced mobility~* History of deep vein thrombosis, pulmonary embolism or stroke, including evidence of prior DVT on duplex ultrasound~* Major surgery, prolonged hospitalization or pregnancy within 3 months of screening~* Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)~* Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions~* Current alcohol or drug abuse~* Pregnant or lactating women~* Women of childbearing potential not using effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Endovenous ablation+polidocanol injectable microfoam 0.125% (Type: EXPERIMENTAL): Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
- Endovenous ablation+polidocanol injectable micrfoam, 1.0% (Type: EXPERIMENTAL): Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
- endovenous ablation+vehicle (placebo) (Type: ACTIVE_COMPARATOR): endovenous ablation followed by injection of vehicle (placebo) to target vein

Based on this trial design, predict the completion outcome and termination type (if applicable).